BusinessMelinta Therapeutics to Highlight Commitment to Antibiotics and Product Portfolio at MAD-ID 2018 Annual MeetingBy Nasdaq OMXMay 8, 2018, 12:01 PM UTC
BusinessFluidigm Introduces High-Parameter Maxpar Immune Monitoring Panel for Translational and Clinical ResearchBy Nasdaq OMXApr 13, 2018, 8:10 PM UTC
BusinessSummit’s Infectious Diseases Technology Platform Yields Novel Antibiotics with Potential in Global Fight Against GonorrhoeaBy Nasdaq OMXMar 13, 2018, 11:01 AM UTC
BusinessVBI Vaccines Announces Voluntary Delisting from the Toronto Stock ExchangeBy Nasdaq OMXMar 12, 2018, 8:15 PM UTC
BusinessSummit Obtains Innovative Antibiotic Discovery and Development Platform Through Acquisition of Discuva LtdBy Nasdaq OMXDec 23, 2017, 9:00 PM UTC
BusinessBioAegis Therapeutics and the T.H. Chan-Harvard School of Public Health Demonstrate “Delayed Therapy with Plasma Gelsolin Improves Survival in Murine Pneumococcal Pneumonia” at ID WeekBy Nasdaq OMXOct 18, 2017, 5:34 PM UTC
BusinessBioAegis Therapeutics Hires Dr. Mark J. DiNubile as Chief Medical Officer to Spearhead Forthcoming Phase 2 Clinical Trials in Community-Acquired PneumoniaBy Nasdaq OMXOct 13, 2017, 2:00 PM UTC
BusinessSummit Awarded BARDA Contract Worth Up to $62 Million to Support the Development of Ridinilazole for the Treatment of C. difficile InfectionBy Nasdaq OMXSep 11, 2017, 11:00 AM UTC
